Health News Releases

  • Today May 20
August 17, 2016 14:10
Outcomes of Presbia Microlens Surgeries in Korean Study Demonstrate Excellent Results
Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near-vision restoration, announced the 12-month results of the 14 Presbia Flexivue Microlens™ surgeries performed on South Korean
August 16, 2016 13:35
Boehringer Ingelheim launches RE-VECTO global program to capture data on Praxbind® usage in clinical practice
Boehringer Ingelheim today announces its global RE-VECTO program for Praxbind® (idarucizumab), the specific reversal agent for Pradaxa® (dabigatran etexilate).[1,2] Praxbind® is approved to reverse th
August 09, 2016 22:30
With Sleep Medicine Launch, Wolters Kluwer Expands UpToDate Coverage to 24 Specialties
The Health division of Wolters Kluwer, a leading global provider of information and point-of-care solutions for the healthcare industry, announced today that it has added sleep medicine to UpToDate®,
August 09, 2016 09:41
Takeda Receives Marketing Authorization in Canada for NINLARO™(ixazomib) in Relapsed/Refractory Multiple Myeloma
Takeda Pharmaceutical Company Limited (TSE:4502) today announced Takeda Canada has received approval from Health Canada for NINLARO™ (ixazomib) capsules in combination with lenalidomide and dexamethas
August 05, 2016 10:50
Masimo Announces CE Marking for Pediatric O3™ Regional Oximetry
Masimo (NASDAQ: MASI) announced today the CE marking for the pediatric indication for O3™ regional oximetry with the O3 pediatric sensor. Regional oximetry, also referred to as tissue or cerebral oxim
August 03, 2016 11:55
Quintiles and DaVita Clinical Research Announce Strategic Alliance
Quintiles, the world’s largest provider of product development and integrated healthcare services, and DaVita Clinical Research, a wholly-owned subsidiary of DaVita HealthCare Partners Inc., a leader
August 01, 2016 19:55
Takeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma
Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that the Phase 3 ALCANZA clinical trial evaluating ADCETRIS (brentuximab vedotin) in patients
August 01, 2016 10:40
Takeda Reports 1st Quarter 2016 Results with a Strong Start to the Year and Confidence in Management Guidance
Takeda Pharmaceutical Company Limited (TOKYO:4502): Strong first quarter results and confidence in Management Guidance · Underlying revenue grew +9.1%, driven by a +15.3% increase of Takeda's Grow
July 28, 2016 15:30
Mannatech Launches Proprietary Essential Oils Line in Korea
Mannatech®, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, has recently expanded its line of proprietary essential oils and G
July 25, 2016 14:00
Octapharma to Sponsor Two Symposia at the 2016 World Federation of Hemophilia (WFH) World Congress in Orlando, USA
Octapharma will sponsor a range of activities at this year’s WFH World Congress in Orlando, USA, including two symposia and a number of posters and scientific presentations highlighting Octapharma’s r
July 21, 2016 11:25
Seattle Genetics and Takeda Announce Publication of Final Data from ADCETRIS® (Brentuximab Vedotin) Monotherapy Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Classical Hodgkin Lymphoma in Blood
Seattle Genetics, Inc. (NASDAQ:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced the final data of the ADCETRIS (brentuximab vedotin) monotherapy pivotal Phase 2 clinical tria
July 20, 2016 17:35
The European Stroke Organisation and Boehringer Ingelheim launch the “Angels Initiative”, a unique healthcare initiative to improve acute stroke care across Europe
Suffering a stroke is one of the most devastating medical emergencies that can happen to a person. It is also a great challenge for the medical personnel treating the patient, trying to save their pat
July 18, 2016 11:15
Samsung Bioepis' Marketing Authorization Application for SB5 Adalimumab Biosimilar Candidate Accepted for Review by the European Medicines Agency
Samsung Bioepis Co., Ltd. today announced that the European Medicines Agency (EMA) has accepted for review the company’s Marketing Authorization Application (MAA) for SB5, a biosimilar candidate refer
July 15, 2016 10:25
Boehringer Ingelheim and University of Dundee collaborate to develop new class of medicines
Scotland--(BUSINESS WIRE)-- Boehringer Ingelheim and the University of Dundee will join forces in an exciting collaboration with the aim to develop a novel class of medicines that target disease causi
July 14, 2016 17:15
Investing in Cures for Cancer: GE Poised to Lead Industrialization of Cell Therapy Industry with Acquisition of Biosafe Group SA
GE Healthcare has acquired Biosafe Group SA, a supplier of integrated cell bioprocessing systems for the rapidly growing cell therapy and regenerative medicine industry for an undisclosed sum. The acq
July 14, 2016 13:40
Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer
Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced a new collaboration on a Phase 1b study that will evaluate the safety and tolerability of BI 836845, Boehringer Ingelheim’s in
July 08, 2016 11:55
One of the World’s Leading Centers for Cardiovascular Medicine & Transplantation Adopts Masimo’s SedLine® Brain Function Monitoring and O3™ Regional Oximetry
Masimo (NASDAQ: MASI) announced today that Deutsches Herzzentrum Berlin (DHZB / German Heart Center Berlin) in Berlin, Germany, has adopted Masimo’s SedLine® Brain Function Monitoring and O3™ Regional
July 07, 2016 14:10
Takeda Receives European Commission Approval of ADCETRIS® (brentuximab vedotin) for Consolidation Treatment in Post-Transplant Hodgkin Lymphoma
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Commission (EC) has extended the current conditional marketing authorization of ADCETRIS® (brentuximab vedotin) and
July 06, 2016 13:50
Takeda Submits a New Drug Application for Novel, Oral Proteasome Inhibitor Ixazomib in Japan
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that it has submitted a New Drug Application (“NDA”) to the Ministry of Health, Labour and Welfare in Japan for ixazomib, the first or
July 04, 2016 13:40
Takeda to Partner with Altos Therapeutics to Develop Promising Compound for the Treatment of Gastroparesis
Takeda Pharmaceutical Company Limited (TOKYO:4502) and Altos Therapeutics LLC today jointly announced the companies have entered into a definitive agreement to further the development of Altos’s propr
June 30, 2016 18:10
INMARK™ now enrolling: first study to evaluate the effect of OFEV® (nintedanib) on biomarkers reflecting the underlying fibrotic process in IPF patients
Boehringer Ingelheim today announces that the first patient has been enrolled in a new study, INMARK™, investigating the effect of OFEV® (nintedanib) on changes in specific blood biomarkers. These cha
June 28, 2016 09:00
Mannatech Redefines Weight Loss Industry with Launch of New Fat-Loss System, TruHealth™ In Korea
Mannatech®, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, today launched its first-ever fat-loss system, TruHealth, to thous
June 27, 2016 17:36
New analysis of INPULSIS® trials demonstrates efficacy of OFEV® (nintedanib) across a range of IPF patients using broader diagnostic criteria
New analysis of the INPULSIS® trials show for the first time that disease progression is similar in idiopathic pulmonary fibrosis (IPF) patients identified using a broader diagnostic definition compar
Photo: Business Wire
June 27, 2016 15:51
Sanofi and Boehringer Ingelheim Have Reached Definitive Agreements to Swap Sanofi’s Animal Health and Boehringer Ingelheim’s Consumer Healthcare Businesses
Sanofi and Boehringer Ingelheim announced today the signing of contracts to secure the strategic transaction initiated in December 2015 which consists of an exchange of Sanofi’s animal health business
June 27, 2016 10:30
Quintiles Introduces Continuous Glucose Monitoring Services to Improve Diabetes Outcomes
Quintiles today announced the launch of its new Continuous Glucose Monitoring (CGM) service offering. This new solution combines innovative, wearable technology with Quintiles’ deep therapeutic and an
25 per page50 per page75 per page100 per page